CLINICAL TRIALS PROFILE FOR THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

All Clinical Trials for THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000575 ↗	Childhood Asthma Management Program (CAMP) Phases I (Trial), II (CAMPCS), III (CAMPCS/2), and IV (CAMPCS/3)	Completed	CAMP Steering Committee	Phase 3	1991-09-01	The purpose of this study is to evaluate the long term effects of anti-inflammatory therapy compared to bronchodilator therapy on the course of asthma, particularly on lung function and bronchial hyperresponsiveness, and on physical and psychosocial growth and development.
NCT00000575 ↗	Childhood Asthma Management Program (CAMP) Phases I (Trial), II (CAMPCS), III (CAMPCS/2), and IV (CAMPCS/3)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1991-09-01	The purpose of this study is to evaluate the long term effects of anti-inflammatory therapy compared to bronchodilator therapy on the course of asthma, particularly on lung function and bronchial hyperresponsiveness, and on physical and psychosocial growth and development.
NCT00000575 ↗	Childhood Asthma Management Program (CAMP) Phases I (Trial), II (CAMPCS), III (CAMPCS/2), and IV (CAMPCS/3)	Completed	Johns Hopkins Bloomberg School of Public Health	Phase 3	1991-09-01	The purpose of this study is to evaluate the long term effects of anti-inflammatory therapy compared to bronchodilator therapy on the course of asthma, particularly on lung function and bronchial hyperresponsiveness, and on physical and psychosocial growth and development.
NCT00000577 ↗	Asthma Clinical Research Network (ACRN)	Withdrawn	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1993-09-01	This study will establish a network of interactive asthma clinical research groups to evaluate current therapies, new therapies, and management strategies for adult asthma.
NCT00000577 ↗	Asthma Clinical Research Network (ACRN)	Withdrawn	Milton S. Hershey Medical Center	Phase 3	1993-09-01	This study will establish a network of interactive asthma clinical research groups to evaluate current therapies, new therapies, and management strategies for adult asthma.

Clinical Trial Conditions for THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

Condition Name

Condition Name for THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER
Intervention	Trials
Asthma	22
Chronic Obstructive Pulmonary Disease	9
COPD	8
Lung Diseases	6

Condition MeSH

Condition MeSH for THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER
Intervention	Trials
Asthma	21
Lung Diseases	19
Pulmonary Disease, Chronic Obstructive	18
Lung Diseases, Obstructive	14

Clinical Trial Locations for THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

Trials by Country

Trials by Country for THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER
Location	Trials
United States	143
China	26
Japan	19
Canada	13
United Kingdom	12

Trials by US State

Trials by US State for THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER
Location	Trials
California	13
Missouri	11
Colorado	11
Texas	10
Tennessee	8

Clinical Trial Progress for THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	2
PHASE2	3

Clinical Trial Status

Clinical Trial Status for THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Completed	72
Unknown status	14
Recruiting	11

Clinical Trial Sponsors for THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER
Sponsor	Trials
National Heart, Lung, and Blood Institute (NHLBI)	10
Washington University School of Medicine	6
The First Affiliated Hospital of Guangzhou Medical University	4

Sponsor Type

Sponsor Type for THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER
Sponsor	Trials
Other	135
Industry	33
NIH	13

Last updated: May 1, 2026

What is the clinical and market outlook for Theophylline and Dextrose 5% in a plastic container?

What clinical-trial evidence supports this product?

No sufficient, product-specific clinical-trials dataset is available to support a clean “clinical trials update” for Theophylline and Dextrose 5% in plastic container as a distinct, investigational product line. Public clinical-trials registries and biomedical literature typically report:

• theophylline trials (often for bronchospasm/COPD or asthma, with many routes and formulations),
• dextrose 5% as a diluent or IV fluid,
• and not a single, identifiable “theophylline + D5% in plastic container” combination as a stand-alone modern development program.

As a result, a complete and accurate update cannot be produced for trial phases, enrollment, endpoints, timelines, or registrational studies tied to this exact presentation.

---

How does the product fit the market for IV theophylline and D5W?

Theophylline remains a long-established bronchodilator with decades of clinical use. In parallel, Dextrose 5% in water (D5W) is a widely used IV fluid and diluent across hospital formularies. The commercial reality for “theophylline in D5%” is generally driven by:

• hospital substitution patterns across IV bronchodilator options,
• availability and procurement costs for specific pack sizes and container types (plastic),
• and formulary preference for alternative theophylline presentations (or other bronchodilators) in acute care.

A structured market projection for the exact product presentation (theophylline + D5% in plastic container) depends on sales-by-NDC/pack, channel mix, and geography. That granularity is not provided in the available materials required to produce a complete and accurate forecast.

---

Can a market projection be stated for this exact presentation?

No. A credible projection requires at least one of the following for the exact product:

• sales series tied to the precise formulation and container configuration (by NDC/GTIN or equivalent),
• payer/provider volumes by pack,
• or a documented pipeline and regulatory position for an identifiable new product.

Without those product-specific anchors, any numeric projection would be incomplete and not reliably attributable to “Theophylline and Dextrose 5% in plastic container.”

---

Business-useful decision points (without fabricating numbers)

What are the realistic drivers of demand?

Demand for IV theophylline formulations typically tracks:

• acute respiratory care utilization (bronchospasm management and escalation pathways),
• hospital formulary and substitution protocols,
• procurement and contract pricing for IV bronchodilators and IV fluids,
• supply continuity and container/handling requirements (plastic containers reduce certain operational risks versus older glass presentations).

What are the realistic margin and risk factors?

For established IV combinations, commercial outcomes often hinge on:

• raw-material cost of theophylline and D5W inputs,
• manufacturing yield and container-fill economics,
• stability and shelf-life constraints tied to IV admixture and storage,
• and competitive pressure from other bronchodilators (and alternative theophylline routes/formulations).

What would move the competitive position?

Competitive position typically improves when a manufacturer can document:

• consistent supply at contracted volumes,
• stable shelf-life and logistics performance,
• and favorable price-per-therapy unit versus alternative IV options on hospital contracts.

---

Key Takeaways

• A complete, accurate clinical-trials update for Theophylline and Dextrose 5% in plastic container as a distinct product cannot be compiled from available public evidence without creating an incomplete or non-attributable summary.
• A complete, accurate market analysis and numeric projection for this exact presentation cannot be produced without product-specific sales/volume anchors.
• The commercial picture for IV theophylline formulations is mainly driven by hospital acute-care demand patterns, formulary substitution, and procurement economics, with container configuration influencing logistics and contract selection.

---

FAQs

1) Is this product considered investigational?

No determination can be made for this exact product presentation from the available information. Theophylline is an established drug, but the specific “theophylline + D5% in plastic container” presentation may be marketed as an approved product or distributed under different regulatory/labeling contexts depending on jurisdiction.

2) Do clinical trials of theophylline translate directly to theophylline in D5%?

Not reliably. Theophylline’s evidence base does not automatically map to a particular IV solution pairing, container type, concentration, stability profile, or route-specific administration details for this exact presentation.

3) What is the main use setting for IV theophylline with IV fluids?

Typically acute care settings where IV bronchodilation is indicated and IV fluid platforms are used for administration, but product-specific confirmation requires labeling and hospital use data not provided here.

4) What metrics matter most for market sizing of this presentation?

Sales by exact formulation and container configuration (NDC/GTIN-level), hospital channel penetration, pack size distribution, and contract pricing versus alternative IV bronchodilator options.

5) What would be the strongest basis for a forecast?

A time series of unit sales or revenue for this exact presentation, aligned to hospital admissions/respiratory admissions trends and to formulary/contract award cycles.